Baxiva AG

Baxiva is pioneering a new frontier in infectious disease prevention. E. coli is responsible for the vast majority of urinary tract infections (UTIs) and is the leading cause of bacterial sepsis worldwide, yet no effective preventative solution currently exists.

Founded in June 2025 and headquartered in Schlieren, Baxiva is developing the first-in-class E. coli vaccine designed to prevent UTIs and their severe complications. Our patented technology platform is a breakthrough in vaccine innovation, offering the flexibility and precision to target bacterial pathogens that have, until now, been beyond reach.